News Aubagio for Relapsing-Remitting MS Now Funded in Alberta Aubagio for Relapsing-Remitting MS Now Funded in Alberta by Patricia Silva, PhD | December 2, 2014 Share this article: Share article via email Copy article link Genzyme, a Sanofi company with over 30 years of dedication to researching and developing novel treatments for rare and orphan diseases, has just announced the Alberta Drug Program has finally decided to include AubagioĀ® (teriflunomide) 14mg in the provincial drug formulary, indicated for the first-line treatment of patients withĀ relapsing remitting multiple sclerosis (RRMS). Alberta, Canada has one of the highest rates of MS worldwide, with over 14,000 residents diagnosed with some form of this neurodegenerative, autoimmune disease. Now, more Albertans with MS can gain access to Aubagio, a novel, orally stable drug capable of reducing exacerbations and delaying the development of physical disabilities. Aubagio was first approved in Canada in November of 2013. While the drug’s exact mechanism of action as an immunomodulator and anti-inflammatory is not known, it is thought to greatly reduce the amount of harmful lymphocytes that attack the protective myelin sheath. The drug has performed impressively in over 5,000 study participants across 36 countries, with patients in extension trials still benefitting from the treatment even 10 years later. “It is great news thatĀ AlbertaĀ will now provide access to a new, oral and highly tolerable first-line agent for relapse reduction for patients with relapsing remitting multiple sclerosis,” saidĀ Dr.Ā Jodie Burton, Assistant Clinical Professor, Department of Clinical Neurosciences and Community Health Sciences Member, Hotchkiss Brain Institute at theĀ University of Calgary. “Any addition to the treatment arsenal, particularly an oral one, has been the ongoing hope of patients and care providers alike for many years. We appreciate theĀ Albertagovernment’s decision to fund this agent, which will improve our ability to make treatment options available to our patients.” [adrotate group=”4″] Neil Pierce, the President of the AlbertaĀ and Northwest Territories Division and the national Vice President of Government Relations of the MS Society ofĀ Canada, noted that the society is pleased the province is committed to improving the lives of the many Albertans affected by MS. It was only last year that the provincial government launched “The Way Forward:Ā Alberta’sĀ Multiple Sclerosis Partnership,” and now the drug formulary has added a world class breakthrough MS treatment to its coverage. Print This Page About the Author Patricia Silva, PhD PatrĆcia holds a PhD in medical microbiology and infectious diseases from the Leiden University Medical Center, Netherlands, and completed a postdoctoral research fellowship at the Instituto de Medicina Molecular, Lisbon, Portugal. Her work in academia was mainly focused on molecular biology and the genetic traits of infectious agents such as viruses and parasites. PatrĆcia earned several travel awards to present her work at international scientific meetings. She is a published author of several peer-reviewed science articles. Tags Aubagio, Canada, Genzyme, relapsing remitting multiple sclerosis, RRMS, Sanofi, teriflunomide
April 25, 2024 Columns by Benjamin Hofmeister Finding safety while living with the constant threat of MS progression
April 25, 2024 News by Margarida Maia, PhD Having MS may marginally increase likelihood of cervical cancer: Study
April 25, 2024 News by Marisa Wexler, MS MS patients prefer Tysabri injection to intravenous infusion: Study